5 results on '"Marinela Augustin"'
Search Results
2. Supplementary Tables S1-S7 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
- Author
-
Stefan Fröhling, Hanno Glimm, Wilko Weichert, Daniel Hübschmann, Evelin Schröck, Albrecht Stenzinger, Benedikt Brors, Barbara Klink, Christof von Kalle, Klaus Schulze-Osthoff, Michael Bitzer, Karsten Spiekermann, Philipp J. Jost, Nikolas von Bubnoff, Anna L. Illert, Melanie Boerries, Thomas Kindler, Christian H. Brandts, Jens Thomas Siveke, Sebastian Bauer, Gunnar Folprecht, Frederick Klauschen, Ulrich Keilholz, Richard F. Schlenk, Peter Schirmacher, Matthias Kroiss, Peter Hohenberger, Walter E. Aulitzky, Marinela Augustin, Ivo Buchhalter, Bettina Meißburger, Christina Geörg, Katrin Pfütze, Stephan Wolf, Ulrike Winter, Daniela Richter, Katja Beck, Roland Penzel, Olaf Neumann, Volker Endris, Andreas Laßmann, Leo Ruhnke, Michael Allgäuer, Daniel B. Lipka, Christoph E. Heilig, Veronica Teleanu, Dorothea Hanf, Lino Möhrmann, Laura Gieldon, Andreas Rump, Arne Jahn, Sebastian Uhrig, Martina Fröhlich, Jennifer Hüllein, Andreas Mock, Barbara Hutter, Simon Kreutzfeldt, Christoph Heining, and Peter Horak
- Abstract
This excel file contains supplementary tables S1-S7.
- Published
- 2023
3. Supplementary Methods from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
- Author
-
Stefan Fröhling, Hanno Glimm, Wilko Weichert, Daniel Hübschmann, Evelin Schröck, Albrecht Stenzinger, Benedikt Brors, Barbara Klink, Christof von Kalle, Klaus Schulze-Osthoff, Michael Bitzer, Karsten Spiekermann, Philipp J. Jost, Nikolas von Bubnoff, Anna L. Illert, Melanie Boerries, Thomas Kindler, Christian H. Brandts, Jens Thomas Siveke, Sebastian Bauer, Gunnar Folprecht, Frederick Klauschen, Ulrich Keilholz, Richard F. Schlenk, Peter Schirmacher, Matthias Kroiss, Peter Hohenberger, Walter E. Aulitzky, Marinela Augustin, Ivo Buchhalter, Bettina Meißburger, Christina Geörg, Katrin Pfütze, Stephan Wolf, Ulrike Winter, Daniela Richter, Katja Beck, Roland Penzel, Olaf Neumann, Volker Endris, Andreas Laßmann, Leo Ruhnke, Michael Allgäuer, Daniel B. Lipka, Christoph E. Heilig, Veronica Teleanu, Dorothea Hanf, Lino Möhrmann, Laura Gieldon, Andreas Rump, Arne Jahn, Sebastian Uhrig, Martina Fröhlich, Jennifer Hüllein, Andreas Mock, Barbara Hutter, Simon Kreutzfeldt, Christoph Heining, and Peter Horak
- Abstract
This file contains supplementary methods and references.
- Published
- 2023
4. Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
- Author
-
Stefan Fröhling, Hanno Glimm, Wilko Weichert, Daniel Hübschmann, Evelin Schröck, Albrecht Stenzinger, Benedikt Brors, Barbara Klink, Christof von Kalle, Klaus Schulze-Osthoff, Michael Bitzer, Karsten Spiekermann, Philipp J. Jost, Nikolas von Bubnoff, Anna L. Illert, Melanie Boerries, Thomas Kindler, Christian H. Brandts, Jens Thomas Siveke, Sebastian Bauer, Gunnar Folprecht, Frederick Klauschen, Ulrich Keilholz, Richard F. Schlenk, Peter Schirmacher, Matthias Kroiss, Peter Hohenberger, Walter E. Aulitzky, Marinela Augustin, Ivo Buchhalter, Bettina Meißburger, Christina Geörg, Katrin Pfütze, Stephan Wolf, Ulrike Winter, Daniela Richter, Katja Beck, Roland Penzel, Olaf Neumann, Volker Endris, Andreas Laßmann, Leo Ruhnke, Michael Allgäuer, Daniel B. Lipka, Christoph E. Heilig, Veronica Teleanu, Dorothea Hanf, Lino Möhrmann, Laura Gieldon, Andreas Rump, Arne Jahn, Sebastian Uhrig, Martina Fröhlich, Jennifer Hüllein, Andreas Mock, Barbara Hutter, Simon Kreutzfeldt, Christoph Heining, and Peter Horak
- Abstract
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-genome/exome and RNA sequencing to inform the care of adults with incurable cancers. On the basis of 472 single and six composite biomarkers, a cross-institutional molecular tumor board provided evidence-based management recommendations, including diagnostic reevaluation, genetic counseling, and experimental treatment, in 88% of cases. Recommended therapies were administered in 362 of 1,138 patients (31.8%) and resulted in significantly improved overall response and disease control rates (23.9% and 55.3%) compared with previous therapies, translating into a progression-free survival ratio >1.3 in 35.7% of patients. These data demonstrate the benefit of molecular stratification in rare cancers and represent a resource that may promote clinical trial access and drug approvals in this underserved patient population.Significance:Rare cancers are difficult to treat; in particular, molecular pathogenesis–oriented medical therapies are often lacking. This study shows that whole-genome/exome and RNA sequencing enables molecularly informed treatments that lead to clinical benefit in a substantial proportion of patients with advanced rare cancers and paves the way for future clinical trials.See related commentary by Eggermont et al., p. 2677.This article is highlighted in the In This Issue feature, p. 2659
- Published
- 2023
5. Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study
- Author
-
Johannes Duell, Pau Abrisqueta, Marc Andre, Marinela Augustin, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami J. Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, and Gilles Salles
- Subjects
Cancer Research ,Oncology - Abstract
Background: Tafasitamab, an anti-CD19 immunotherapy that enhances antibody-dependent cellular cytotoxicity and phagocytosis, received accelerated approval in the USA and conditional authorization in Europe in combination with lenalidomide (LEN) for patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) based on the results of the open-label, multicenter, single-arm, Phase II L-MIND study (NCT02399085; Salles G, et al. Lancet Oncol 2020, Duell J, et al. Haematologica 2021). Here, we report the final, 5-year follow-up of L-MIND. Data cut-off was Nov 14, 2022. Methods: Pts were aged ≥18 years with ASCT-ineligible R/R DLBCL, 1-3 prior systemic therapies (including a CD20-targeting regimen), and ECOG PS 0-2. Tafasitamab (12 mg/kg) was given for up to 12 cycles in combination with LEN (25 mg), then as monotherapy until disease progression (PD) or unacceptable toxicity. The primary endpoint was best objective response rate (ORR; complete response [CR] or partial response [PR], by independent radiology committee). Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and incidence and severity of adverse events (AEs). Exploratory analyses evaluated efficacy endpoints by prior lines of therapy (pLoT). Results: Of 81 pts enrolled, 80 were treated (full analysis set [FAS]). The ORR (FAS) of 57.5% [95% CI: 45.9-68.5], with CR of 41.2% [30.4-51.6] (n=33) and PR of 16.2% [8.9-26.2] (n=13), was generally consistent with the primary and 3-year analyses. Median DoR was not reached (NR) with median follow up (mFU) of 44.0 months [29.9-57.0]. Median PFS was 11.6 months [5.7-45.7] (mFU 45.6 [22.9-57.6]) and median OS was 33.5 months [18.3-NR] (mFU 65.6 [59.9-70.3]). At data cut-off, OS was >60 months in 21 pts (18 with best response of CR, 1 PR, 1 stable disease and 1 PD), including 14 with 1 pLoT and 7 with ≥2 pLoT. Pts with 1 pLoT (n=40) in the FAS had higher ORR (67.5%; 52.5% CR [n=21] and 15% PR [n=6]) compared to pts with ≥2 pLoT (n=40; 47.5%; 30% CR [n=12] and 17.5% PR [n=7]). However, median DoR was not reached for both subgroups, indicating similar long-term efficacy for responders. AEs were consistent with previous reports and manageable; incidence declined after transition from combination to tafasitamab monotherapy and again with monotherapy >2 years. Conclusion: The final, 5-year analysis of L-MIND showed prolonged durable responses with tafasitamab + LEN combination therapy, followed by long-term tafasitamab monotherapy, in pts with R/R DLBCL ineligible for ASCT, with median DoR not reached after 44 months mFU. No new safety signals were identified, confirming the tolerability profile observed with earlier data cuts. These long-term data suggest that this immunotherapy may have curative potential that is being explored in further studies. Citation Format: Johannes Duell, Pau Abrisqueta, Marc Andre, Marinela Augustin, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami J. Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles. Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT022.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.